EPA023 Immunotherapeutic blockades targeting LAG-3 and PD-1 immune checkpoint inhibitors on invariant Natural Killer T cells: implications in chronic HIV infectionE-posterInnate immunity (including NK cells)
EPA024 The effects of in utero HIV and anti-retroviral therapy exposure on infant T-cell and monocyte activation, function and regulation of immune-modulatory pathwaysE-posterInnate immunity (including NK cells)
EPA025 HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotypesE-posterInnate immunity (including NK cells)
EPA026 Characterizing the effect of intracellular storage pools of RANTES/CCL5 on HIV infection in macrophagesE-posterInnate immunity (including NK cells)
EPA027 HIV-1 Vpu limits Fc-mediated effector functions in vivoE-posterHumoral immunity (including broadly neutralizing antibodies), Antibodies and B cells
EPA028 Metabolic gene profiling of activated, terminally differentiated effector memory and exhausted CD8+ T cells in people living with HIVE-posterCellular immunity; T cell vaccines
EPA029 BNT162b2 vaccine elicits impaired B cell and CD8 T cell responses combined with skewed CD4 T responses in patients receiving hemodialysisE-posterCellular immunity; T cell vaccines
EPA030 HIV-1-specific T-cells in an HIV-1-infected but HIV-1 antibody negative patient on long-term antiretroviral therapyE-posterCellular immunity; T cell vaccines
EPA031 Pomalidomide drives expansion of HIV-specific CD8+ T cells and enhances NK cell cytotoxicity to augment anti-HIV immunityE-posterCellular immunity; T cell vaccines
EPA032 Virtual memory CD8+ T-cells exhibit highly cytotoxic profiles in people with HIV, and are expanded by N-803E-posterCellular immunity; T cell vaccines
21 - 30 of 2486 items